Post imported by Google+Blog for WordPress.
"On top of opposition from animal rights groups, more scientists are claiming that animal studies do not accurately predict the human response to drugs or beauty products, especially ones that are used on a regular basis. At the same time, using human cells for safety testing is not practical because they die after a few days outside of the body."
"To address this challenge, the researchers have created a liver-on-a-chip device, also known as a 3D micro-reactor, which mimics human physiology using nanotech-based optoelectronic sensors."
"When testing Tylenol using the technology’s sensors, the researchers were able to detect small, rapid changes in cellular respiration that have never been observed before – suggesting potential damage at much smaller dosages than had previously been observed. Scientists had long believed that liver damage from acetaminophen only occurs at high doses and in cases of diseased or compromised liver function."
"Yissum, the tech transfer arm of Hebrew University, together with the Fraunhofer Institute, submitted a joint provisional patent application earlier this year and are seeking industry partners to take the liver-on-a-chip to market. The global market for this technology is estimated to be worth $17 billion by 2018."
Researchers in Israel and Germany develop potential alternative to animal testing – Tech Transfer e-News – Tech Transfer Central
Researchers at Hebrew University of Jerusalem and the Fraunhofer Institute for Cell Therapy and Immunology in Germany have developed a technology that coul
"Back in 2012, Congress reformed intellectual property law to protect tech companies from patent holders that don't seek to make or sell anything, preferring to pursue a strategy of stockpiling patents and suing productive manufacturers for alleged violations. Often trolls seek monetary settlements—a form of perfectly legal extortion—in exchange for dropping patent challenges and returning to their troll lodge."
"Egged on by Silicon Valley, lawmakers in Congress "fixed" the problem by creating a streamlined procedure by which tech companies could preemptively knock out questionable patents and thereby defuse the entire troll gambit. As so often happens, however, the 2012 reform had unintended consequences. Hedge funds began using the accelerated challenge procedure, known as inter partes review, to attack pharmaceutical patents while shorting manufacturers' stock—a way of betting that shares will decline."
From http://ow.ly/RmcOx :
Why This Small Victory Against Short Sellers Might Be a Big Deal for Biotech Companies
A 2012 reform meant to block patent trolls has opened drug makers to attacks by hedge funds
From panic to judgment day, investors struggle to describe rout
Investors, strategists and asset managers across the world struggled for words to describe the selloff